Dexcom
Signal active
Investment Firm
Overview
DexCom is a developer of glucose sensing technologies and focuses on these technologies. Founded in 1999, DexCom's roots stem from the pioneering 1967 research on implanted glucose sensors at the University of Wisconsin. DexCom started with a focus on creating an implantable Sensor that the body would not reject and that would perform for a long period of time.
Highlights
Founded
1999
Industry
Health Care
Employees
5001-10000
Investment
3
Lead Investment
1
Exits
1
Stages
Early Stage Venture
Investor Type
N/A
Location
United States, North America
Contact Information
Social
Profile Resume
Dexcom, established in 1999 and headquartered in United States, North America., specializes in Early Stage Venture investments across Biotechnology, Life Science, Health Care, Wellness, Hospital, Medical, Precision Medicine, Medical Device, Home Health Care, Financial Services. The organization boasts a portfolio of 3 investments, with an average round size of $24.2M and 1 successful exits. Their recent investments include Phenomix Sciences, Health2047, LabCorp, Current Health, MMC Ventures. The highest investment round they participated in was $4.1B. Among their most notable exits are Phenomix Sciences and Health2047. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
Investment portfolio
Dexcom has made 3 investments. Their most recent investment was on May 06, 2024, when Phenomix Sciences raised $5.5M.
Dexcom has made 1 diversity investments. Their most recent diversity investment was on Jan 08, 2019, when Beta Bionics raised $63.0M.
investments
3
Diversity investments
1
Lead investments
1
Number of exits
1
Investments
3
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jan 08, 2019 | Beta Bionics | Biotechnology | 63.0M |
| Jun 17, 2020 | Current Health | Health Care | 4.2M |
| May 06, 2024 | Phenomix Sciences | Biotechnology | 5.5M |
Exits
1
Funding Timeline
Funding rounds
3
Investors
7
Funds
1
Funding Rounds
3
Dexcom has raised 3 rounds. Their latest funding was raised on May 06, 2024 from a Series A - Phenomix Sciences round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jan 08, 2019 | Series B - Beta Bionics | - | 63.0M | - |
| Jun 17, 2020 | Series A - Current Health | - | 4.2M | - |
| May 06, 2024 | Series A - Phenomix Sciences | - | 5.5M | - |
Investors
16
Dexcom is funded by 16 investor(s). Canaan Partners and Warburg Pincus Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
| - | No | Post-IPO Debt - Dexcom | 350.0M |
| - | No | Post-IPO Equity - Dexcom | 750.0M |
| - | No | Post-IPO Debt - Dexcom | 0 |
| - | No | Post-IPO Debt - Dexcom | 1000.0M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.